Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J, Distributors May Be Free Of Opioid Litigation If Enough States Sign On To $26bn Settlement

Executive Summary

NY AG has ‘no comment’ on whether criminal charges will be pursued against company executives; NC AG predicts ‘north of 40 states’ expected to accept settlement and would then need to convince municipalities to come on board. States with ongoing litigation against manufacturers may opt for jury trial instead. 

You may also be interested in...



Selling Opioids Is Not A Public Nuisance For Three Reasons, Oklahoma State Appeals Court Rules

Overturning a $465m verdict against J&J, Oklahoma Supreme Court rejects claim opioid sales violated a public right. It says a manufacturer does not have control of its product once it is sold and cannot be held perpetually liable for its products.

Can California Opioid Ruling Help Manufacturers In Pending Cases?

Judge’s dismissal of all claims against opioid makers offers hope they can win other cases and may push forward settlements. But it is ‘bookend’ by the Oklahoma case that reached a dramatically divergent conclusion, so while significant, it is only a single data point, Stanford law professor says.

Opioid Prescriber Education Program May Become Mandatory; FDA Cites Failures In Voluntary System

US regulators set public workshop on benefits, challenges, and unintended consequences of making REMS education program mandatory. Having a single source for education is also being evaluated. Agency has previously been concerned that a mandatory program might require a restricted distribution system.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel